Response Genetics Inc. announced that it has entered into an agreement with MultiPlan Inc. As a participating provider in the PHCS and MultiPlan Networks, MultiPlan's clients will now have access to all of Response Genetics' molecular diagnostic testing. Response Genetics specializes in predictive genomic testing that supplies treating physicians with actionable information helping the physicians determine what drugs will have the response from each of their patients battling lung, colorectal, gastric and melanoma cancers. The personalized nature of Response Genetics' testing allows for each patient to be placed on the most effective drug regimen for his or her cancer treatment.